Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

Approximately 20-33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubility of palbocic...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2022-05, Vol.22 (1), p.516-516, Article 516
Main Authors: Eser, Kadir, Önder, Arif Hakan, Sezer, Emel, Çil, Timuçin, İnal, Ali, Öztürk, Banu, Erçolak, Vehbi, Duman, Berna Bozkurt, Çelik, Halil, Köşeci, Tolga, Kesen, Oğuzhan
Format: Article
Language:English
Subjects:
Aminopyridines
Antineoplastic Agents - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Care and treatment
Complications and side effects
Diagnosis
Dosage and administration
Drug Interactions
Female
Fulvestrant
Gastroesophageal reflux
Humans
Letrozole
Metastasis
Palbociclib
PFS
Piperazines
Prevention
Protein Kinase Inhibitors - therapeutic use
Proton pump inhibitors
Proton Pump Inhibitors - adverse effects
Proton Pump Inhibitors - therapeutic use
Purines
Pyridines
Receptor, ErbB-2 - therapeutic use
Retrospective Studies
Ribociclib
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Approximately 20-33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms. Palbociclib and ribociclib are weak bases so their solubility depends on different pH. The solubility of palbociclib dramatically decreases to 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-022-09624-y